Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Systemic review and meta-analysis: Treatment-related adverse events of neoadjuvant immune checkpoint inhibitors.

Guo Cheng Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e14581

e14581 Background: Immune checkpoint inhibitors (ICIs) are increasingly used in cancer treatment, with recent expansion in...

Neoadjuvant androgen receptor pathway inhibition for patients with high-risk localized prostate cancer: 5-year survival update and PSMA PET correlatives of the randomized NeoPRO trial.

Gabriel Berlingieri Polho, Gabriella Soares, David Queiroz Borges Muniz et al. Jun 01, 2026 pp. 5119-5119 10.1200/jco.2026.44.16_suppl.5119

5119 Background: Patients with high-risk prostate cancer remain at elevated risk of recurrence after local therapy. Ongoin...

Real-world survival outcomes with pembrolizumab plus chemotherapy in advanced triple-negative breast cancer: Multicenter evidence from Poland, the Czech Republic, and Slovakia.

Miroslawa Puskulluoglu, Joanna Kiszka, Aleksandra Konieczna et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13118

e13118 Background: In KEYNOTE-355, pembrolizumab plus chemotherapy improved efficacy versus chemotherapy alone in first-li...

Real-world outcomes of biomarker-intended pembrolizumab use in soft tissue sarcomas.

Keun Lee, Hyun Lee Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23574

e23574 Background: Pembrolizumab has a tissue-agnostic FDA indication for metastatic or unresectable solid tumors with hig...

Impact of liquid biopsy training on real-world testing practices for advanced NSCLC across Latin America: The OMEGA (LACOG 0424/GBOT) survey.

Leonardo Gil Santana, Erick F. Saldanha, William Nassib William et al. Jun 01, 2026 pp. 9029-9029 10.1200/jco.2026.44.16_suppl.9029

9029 Background: The therapeutic landscape of non-small cell lung cancer (NSCLC) has evolved with advances in genomic prof...

Comprehensive characterization of HIF-2α and carbonic anhydrase IX expression and the genomic landscape in clear cell and <i>VHL</i> -altered renal cell carcinoma.

Yu-Wei Chen, Shayan S. Nazari, Andrew Elliott et al. Jun 01, 2026 pp. 4543-4543 10.1200/jco.2026.44.16_suppl.4543

4543 Background: Clear cell renal cell carcinoma (ccRCC) is commonly driven by VHL loss, resulting in HIF-2α stabilization...

Development and validation of a National Database–derived nomogram for predicting postoperative survival in colorectal cancer.

Mohyeddine El Sayed, Calvin Widholm, Elizabeth Goodwin Hill et al. Jun 01, 2026 pp. 3669-3669 10.1200/jco.2026.44.16_suppl.3669

3669 Background: Prognosis after curative-intent surgery for colorectal cancer remains heterogeneous and incompletely expl...

Emotional health concerns due to kidney cancer (KC) and unmet needs in patient support: Results from the International Kidney Cancer Coalition (IKCC) Global Patient Survey (GPS).

Eric Jonasch, Axel Bex, Saeed Dabestani et al. Jun 01, 2026 pp. 4532-4532 10.1200/jco.2026.44.16_suppl.4532

4532 Background: KC negatively impacts the emotional well-being of patients, and patient support services are a critical c...

First-in-human study of cavitation-enhanced drug delivery (CEeDD) by sonosensitive particles and focused ultrasound applied to colorectal metastases in the liver.

Jeffrey Rubasingham, Calum Crake, Christian Coviello et al. Jun 01, 2026 pp. 3549-3549 10.1200/jco.2026.44.16_suppl.3549

3549 Background: Effective treatment of colorectal liver metastases is limited by poor drug delivery, particularly for mon...

Infection-associated transitions to critical care–level interventions in adult cancer hospitalizations: A National Inpatient Sample analysis.

Jithin Mathew, Chandelle Nichols, Saeid Kheirollah et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23214

e23214 Background: Infectious diagnoses and complications during cancer hospitalizations are commonly evaluated using stat...

Feasibility assessment of a global, anonymized, human-in-the-loop AI decision-support platform for oncology second opinions following a live demo at an international symposium.

Laura Alder, Kathryn E. Beckermann, Adam E. Singer et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13672

e13672 Background: There are widespread disparities in access to rapid, expert-level second opinions worldwide. We assesse...

A trial to evaluate CSF ctDNA and safety of plixorafenib alone or with retifanlimab in patients with BRAF-altered glioma.

Karisa C. Schreck, Peng Huang, Michaella Iacoboni et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps2100

TPS2100 Background: BRAF V600E mutant gliomas are difficult to treat in the recurrent setting due to adaptive resistance t...

Data-driven precision prognostic stratification in breast cancer leptomeningeal metastasis: The BC-LGPA model and treatment refinement.

Jian Zhang, Yuxin Yan, Wei Li et al. Jun 01, 2026 pp. 1114-1114 10.1200/jco.2026.44.16_suppl.1114

1114 Background: Breast cancer leptomeningeal metastasis (BCLM) lacks data-driven prognostic models integrating diagnostic...

Impact of locoregional treatments in oligometastatic squamous cell anal carcinoma.

Valentina Zen, Giulia Maddalena, Rossana Intini et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15502

e15502 Background: Squamous cell anal carcinoma (SCAC) is a rare malignancy with limited therapeutic options in the metast...

Bevacizumab-based triplet versus doublet chemotherapy as first-line treatment for metastatic right-sided colon cancer: Results of the KCSG CO19-18 phase II trial.

Jee Hung Kim, Hyunwook Kim, Myung Ah Lee et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15562

e15562 Background: The prognostic significance of primary tumor location in colorectal cancer has recently gained attentio...

Secondary safety analysis of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in DESTINY-Breast05: Clinical and demographic risk factors of interstitial lung disease (ILD) and radiation pneumonitis (RP).

Michael Untch, Zhimin Shao, Chiun-Sheng Huang et al. Jun 01, 2026 pp. 516-516 10.1200/jco.2026.44.16_suppl.516

516 Background: In DESTINY-Breast05 (NCT04622319), T-DXd showed superior efficacy vs T-DM1 in patients (pts) with human ep...

The GP78-Spatial Aggressiveness Index (GP78-SAI): A race-independent AI-driven biomarker for precision oncology.

Samarth Singhal, Adana A.M. Llanos, Kevin Gardner et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e12566

e12566 Background: GP78 (AMFR) protein expression is associated with breast cancer (BC) progression and poor outcomes (PMC...

Effect of (Z)-endoxifen on estrogen receptor signaling inhibition across clinically relevant <i>ESR1</i> mutations.

Sandra Hammer, Junping Wei, Gangjun Lei et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15155

e15155 Background: Activating mutations in the estrogen receptor alpha gene (ESR1) are a key mechanism of resistance to en...

Adverse effects of immune checkpoint inhibitors in locally advanced head and neck squamous cell carcinoma: A meta-analysis of randomized trials.

Rishi Kumar Nanda, Daniel Thomas Jones, Ramaditya Srinivasmurthy et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24179

e24179 Background: Immune checkpoint inhibitors (ICIs) have improved outcomes in recurrent and metastatic head and neck sq...

Comparative analysis of mortality trends in acute versus chronic myeloid leukemia in the U.S. population with time series projection: A CDC WONDER–based study (1999–2023).

Muhammad Saim, Anid Hassan, Sheraz Qasim et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18501

e18501 Background: Myeloid leukemias (ML) pose a significant public health concern globally and in the United Stat...

Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD, + Pola-RCHP in patients (pts) with newly diagnosed aggressive B-cell lymphoma (a-BCL): Safety and 12-month (mo) efficacy results.

Marc S. Hoffmann, Grzegorz S. Nowakowski, Michal Kwiatek et al. Jun 01, 2026 pp. 7011-7011 10.1200/jco.2026.44.16_suppl.7011

7011 Background: Up to 40% of pts with diffuse large B-cell lymphoma (DLBCL) will relapse or have refractory disease follo...

High-volume patient navigator encounters and access to oncology clinical trials.

Tanya Jindal, Sylvia Zhang, Amanda Pratt et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23227

e23227 Background: Only 7% of US adults with cancer enroll in clinical trials, despite a rising number of clinical trials...

Ranking neoantigens for escape-resilience rather than predicted immunogenicity: Associated changes in vaccine design.

Michael E. Bryan, Miles Weatherseed, Om H. Gandhi et al. Jun 01, 2026 pp. 2654-2654 10.1200/jco.2026.44.16_suppl.2654

2654 Background: Personalised neoantigen vaccines induce detectable CD8 + T cell r...

Enhancing recruitment of AYAs with Hodgkin lymphoma through community partnerships: Prioritizing diverse populations.

Raymond Mailhot Vega, Robin Cacchio, Audrey Gardner et al. Jun 01, 2026 pp. 11026-11026 10.1200/jco.2026.44.16_suppl.11026

11026 Background: Hodgkin lymphoma (HL) is one of the most common cancers affecting adolescents and young adults (AYAs). A...

Distinct clinical and genomic landscape of bilateral parenchymal non–small cell lung cancer (NSCLC) using the AACR GENIE BPC database.

Jongwoo Kim, Seoin Kim, João Pedro Thimotheo Batista et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20558

e20558 Background: NSCLC with bilateral lung involvement is currently staged as IV (M1a). However, patients with lung-only...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page